All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Merck & Co.'s Keytruda (pembrolizumab) for PD-L1 positive platinum-resistant ovarian carcinoma second-line treatment
Antibody, cancer, monoclonal antibody, ovarian cancer, PD-L1 target, combination therapy - Read more

THE GOOD
Business Development & Partnerships

Madrigal Pharmaceuticals, Suzhou Ribo Life Science partner on MASH siRNA programs, $60M upfront, $4.4B milestones
Licensing deal, siRNA, MASH, milestone payments, combination therapy - Read more

Zelluna, Medpace partner for ZIMA-101 first-in-human clinical trial in solid cancers
Clinical services partnership, oncology, cell therapy, first-in-human study - Read more

Sanofi, GluBio Therapeutics strategic investment for molecular glue degraders in sickle cell disease, $30M
Equity investment, rare disease, molecular glue degraders, sickle cell disease - Read more

PRESENTED BY FACET LIFE SCIENCES
Facet Life Sciences Makes Emerging Biotech Approvable

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

✅ More Good News ✅

THE GOOD
Clinical Trials

Bioxytran reports complete viral clearance by day 7 with ProLectin-M galectin antagonist in Ph2 acute viral infection trial
Small molecule, infectious disease, galectin antagonist, antiviral, viral clearance - Read more

Upstream Bio's verekitug (TSLP receptor blocker) shows positive Ph2 results in severe asthma treatment
Antibody, asthma, monoclonal antibody, TSLP receptor, severe asthma - Read more

THE GOOD
Company Incubation

Gubra launches Gubra Ventures with Zoë Johnson leading new independent biotech company creation unit
Cardiometabolic, strategic, operational, venture creation - Read more

THE GOOD
Fundraises

Nasus Pharma raises $15M private placement for NS002 anaphylaxis treatment development
Clinical-stage, intranasal delivery, anaphylaxis, small molecule - Read more

Nektar Therapeutics raises $400M public offering for clinical development and manufacturing costs
Clinical-stage, immunotherapy, oncology, rezpegaldesleukin - Read more

Gyala Therapeutics receives €3.7M ($4.4M) government funding for Phase I/IIa cancer trial
Clinical-stage, cell therapy, hematologic cancers, oncology - Read more

Galecto raises $275M public offering, developing therapeutics for blood cancers
Blood cancers, oncology, biopharmaceutical, clinical-stage - Read more

THE GOOD
Investments

Fujifilm Biotechnologies announces £400M ($545.3M) UK biomanufacturing expansion adding 19,000 liters single-use capacity for medicines and vaccines
Biologics, rare disease, strategic, major transaction - Read more

THE GOOD
Lawsuits

GSK and Teva quietly settle decade-long Coreg skinny label patent dispute over heart medication
Small molecule, cardiovascular, strategic, operational - Read more

THE GOOD
Mergers & Acquisitions

IMA Group acquires majority stake in ProSys Sampling Systems to expand global aseptic sampling solutions
Biopharmaceutical equipment, strategic, major transaction, operational - Read more

THE GOOD
Strategic Plans

Takeda consolidates Boston operations, subleasing 630K square feet while opening new Cambridge R&D facility
Cell therapy, operational, strategic, cost reduction - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Earnings & Finances

Gilead Sciences beats Q4 expectations but disappoints with lower 2026 Yeztugo sales forecast
Injectable drug, infectious disease, financial, revenue impact - Read more

THE BAD
Regulatory

FDA refuses to review Moderna's mRNA-1010 influenza vaccine citing inadequate trial design in refusal-to-file letter
mRNA vaccine, infectious disease, influenza, seasonal flu vaccine, combination therapy - Read more

THE UGLY
Lawsuits

AstraZeneca and former exec Leon Wang indicted in China over illegal data collection and drug importation charges
Monoclonal antibody, oncology, operational, financial - Read more

THE UGLY
Regulatory

FDA's Prasad overruled vaccine teams to refuse review of Moderna's mRNA flu vaccine application
mRNA vaccine, infectious disease, regulatory, operational - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here